SPHK1 and melanoma: Indeed, it has been discovered that patients with low SphK1 expression in melanoma cells had significantly longer progression-free survival and overall survival than those with high SphK1 expression and patients with high SphK1 expression mostly failed to respond to anti-PD-1 therapy [89].